Epiminder Ltd.

Epiminder Ltd.

AASX:EPI
0.27
AUD
0.00
(0.00%)
-0.28EPS
69.33MMarket Cap
Mar 01Next Earn
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
- -
- -
- -
Basic EPS, GAAP
-0.12
-0.13
-0.2
-0.28
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
Book Value per Share
- -
- -
0.61
0.38
Tangible Book Value per Share
- -
- -
0.54
0.32
Basic Weighted Avg Shares
175
175
175
151
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
Net Income, GAAP
-21
-22
-35
-43
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
Working Capital
- -
- -
94
70
LT Debt
- -
- -
- -
- -
Total Equity
- -
- -
107
82
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-64.28
-45.21

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-23.94%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
23.82%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.13
2025
- -
- -
-0.2
2026
- -
- -
-0.28

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Rohan J. Hoare
Sector
Electronic technology
Industry
Electronic equipment/Instruments
Address
West Podium, Mezzanine 2 East Melbourne VIC Australia 3000
IPO Date
Nov 27, 2025
Business
Epiminder Ltd. is a medical device and information solutions company, which focus on developing diagnostic and treatment tools for epilepsy. The company was founded by Mark Cook on 2018 and is headquartered in Melbourne, Australia.